Alligator Bioscience (ATORX) R&D Day 2025 summary

Pipeline overview and program updates

• Mitazalimab is phase III ready, showing strong long-term survival data in metastatic pancreatic cancer, with expansion into additional GI and non-GI cancers planned via investigator-initiated trials starting in H2 2025 and H1 2026.

• ATOR-4066, a bispecific follow-up to mitazalimab, is in preclinical development for more targeted applications.

• HLX22, a HER2 antibody developed by Henlius, is in phase III for gastric cancer and phase II for breast cancer, with Alligator holding future royalty rights and annual royalty estimates of SEK 150–400 million.

Clinical trial data and development milestones

• OPTIMIZE-1 phase II trial showed mitazalimab plus FOLFIRINOX tripled 24-month survival rates and doubled duration of response compared to historical controls, with a median overall survival of 14.9 months.

• Safety profile is favorable, with no added toxicities or cytokine release syndrome observed.

• Biomarker analyses confirm immune activation correlates with improved survival and may inform patient selection.

• Final OPTIMIZE-1 30-month data readout is expected in Q3 2025, after which the trial will be finalized.

• Manufacturing of phase III material for mitazalimab has been successfully completed.

R&D strategy and innovation priorities

• Focus on expanding mitazalimab's clinical footprint through investigator-initiated trials in various tumor types and combinations with other modalities.

• Ongoing biomarker research to refine patient selection and optimize clinical outcomes, highlighting myeloid and T-cell activation linked to improved outcomes.

• Continued development of proprietary antibody technologies and bispecific formats.